A Zinc Play With A Bright Future. Corporate Presentation CSE: PSE FSE: PNX

Size: px
Start display at page:

Download "A Zinc Play With A Bright Future. Corporate Presentation CSE: PSE FSE: PNX"

Transcription

1 A Zinc Play With A Bright Future Corporate Presentation CSE: PSE FSE: PNX

2 Disclaimer The information contained in this presentation is provided by Pasinex Resources Limited. ( Pasinex ) for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Pasinex or other financial products. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. The views, opinions and advice provided in this presentation reflect those of the individual presenters, and are provided for information purposes only. The presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Pasinex nor its directors officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. Except for statements of historical fact, this presentation contains certain forward-looking information within the meaning of applicable securities laws. Forwardlooking information is frequently characterized by words such as plan, expect, project, intend, believe, anticipate, estimate and other similar words, or statements that certain events or conditions may or will occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements, including, among others, the accuracy of mineral grades and related assumptions, planned expenditures, proposed exploration and development at the Golcuk Copper/Silver Project, the Horzum Zinc/Lead Project and the Dadak Copper / Gold Project. Pasinex undertakes no obligation to update forward-looking information if circumstances or management s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. This presentation includes industry, market and competitive position data from industry journals and publications, data on websites maintained by private and public entities, including independent industry associations, general publications and other publicly available information. Pasinex believes that all of these sources are reliable, but we have not independently verified any of this information and cannot guarantee its accuracy or completeness. Industry publications and surveys generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. Further, because certain of these organizations are industry organizations, they may present information in a manner that is more favorable to the industry than would be presented by an independent source. In addition, forecasts are often inaccurate, especially over long periods of time. References in this presentation to research reports or articles should not be construed as depicting the complete findings of the entire referenced report or article. The information in each report or article is not incorporated by reference into this presentation.

3 Pasinex Overview 2019 is a transition year with a mine development program to open up deeper zinc mineralization at Pinargozu in Turkey and exploration on the Spur Project in Nevada. 45,757 wet tonnes zinc produced in 2018 from Pinargozu. Profitable operations with over 65% gross margin first three quarters of guidance is 14,000-17,000 wet tonnes zinc. 3 month production hiatus for mine development. SEDEX intersection on Spur Zinc Project in Nevada. Exploration drill program on Akkaya Project. Large land position in a CRD zinc district in Turkey.

4 Zinc Production & Exploration in Turkey and the US High Grade Zinc Carbonate Production & Exploration at Pinargozu Zinc Mine, Turkey 50/50 JV UNITED STATES NEVADA High Grade Zinc Carbonate Exploration at Akkaya Zinc Project, High Grade Zinc Carbonate Turkey 50/50 JV Exploration Project Spur, White Pine County, Nevada 80% Earn In over 4 years Pasinex Resources Ltd. is active with Zinc Projects on two continents TURKEY

5 Pasinex Corporate Profile Capital Structure CSE:PSE; FSE:PNX Shares Issued and Outstanding Share Price (April 1 st, 2019) Market Capitalisation 144,354,370 $ $ 10.8 M Warrants Options None 4.2 M Shareholders Directors & Management 45% 20% Other Top 20 Shareholders Other Shareholders

6 Pasinex Management & Board Steve Williams President & CEO Metallurgy degree and MBA, Mines in Australia and Canada, 20 years with SGS in Metallurgy, Past Managing Director SGS Canada Evan White Manager, Corporate Communications 11 years in marketing in the mining sector Wendy Kaufman CFO Chartered Professional Accountant with 20 years of international financial experience in mining. Formerly CFO at Primero and VP Finance at Inmet Mining Corp Vic Wells Board Chairman Financial expert was CFO / Director for a number of junior exploration companies John Barry VP. Exploration Master s Degree in Geology from Pennsylvania State University, MBA from the Edinburgh School of Business, Experienced Zn geologist Ex-CEO Rathdowney Resources Dr. Larry Seeley Board Member Ex-VP Falconbridge Mining, Ex-President Lakefield Research Joachim Rainer Board Member 20 years in entrepreneurial finance in Austria Jonathan Challis Board Member Mining engineer with many Directorships and senior roles with juniors

7 A Growing Pure Play Zinc Company v New discovery of zinc sulphide in black shales beneath high-grade zinc oxides in Nevada v Two drill rigs currently drilling at Akkaya Zinc Exploration Project in Turkey. Targets along strike from Pasinex s Pinargozu high-grade zinc oxide mine v Pasinex owns 50% of the Pinargozu Mine which is an exceptionally high grade zinc mine near Adana, Turkey. v Approximately 43,709 wet tonnes of zinc oxide produced in 2018; 2,048 wet tonnes of zinc sulphide. v District & regional exploration opportunity in a world class zinc district in Turkey.

8 Pinargozu Zinc Mine Operating Results Summary of 2018 operating results and 2019 estimates for the Pinargozu mine are as follows: Guidance Horzum AS Reporting as 100% Zinc oxide production (grade) 43,709 (31%) 9,000 10,000 (29 31%) Zinc sulphide production (grade) 2,048 (45%) 5,000 7,000 (45 47%) Total Production 45,757 14,000 17,000 Cost Per Tonne Mined (CAD)* $200 - $220 $450 - $500 *Non-GAAP measures.

9 Spur Zinc Project, Nevada [Exploration] Exciting new zinc sulphide discovery beneath an old high-grade zinc prospect v Small drill programme confirms highgrade zinc oxides and leads to new discovery of deeper zinc sulphides v Possible high-grade Eureka-style CRD system and potential for a major shalehosted-massive-sulphide (SHMS) deposit beneath v Verified high grade zinc oxides: v % zinc v % zinc and 5.6 ounces of silver White Pine County, Nevada, USA v Earn in option agreement whereby Pasinex can earn to up to 80% interest in the project based on payments and exploration commitment

10 Why are Shale-Hosted Zinc Deposits Important? v Black Shale is a highly unusual host for CRD mineralization. SHMS deposits are highly significant for exploration v Shale-hosted massive sulphides zinc deposits (SEDEX or SMHS) are not common but are large, hosting over 18% of the world s zinc v Four of the five largest zinc mines globally are shale hosted. Examples: Red Dog, Sullivan, Selwyn, McArthur River, Hilton

11 Summary Highlights of Drill Assay Results Drill Hole # Core Length Interval Metres Zn Grade % From (metres) Mineralization SRDD Including Oxide in Limestone Oxide in Limestone SRDD Oxide in Limestone Nevada, SRDD White Pine 4.3 County Oxides in Fault Zone SRDD Sulphide in Black-Shale SRDD Sulphide in Black-Shale

12 A Closer Look at Black Shale & Drill Hole SRDD_2018_04 Fossiliferous Limestone Fault Zone Limestone-micrite-clayey siltstone, laminations, no fossils 4.3% Zinc 8.1% Zinc 5.7% Zinc Fault Zone Fault Zone Black Shale-Siltstone-mudstone Gray dolobreccia Carbon Ridge-clastic member 0 20 Metres

13 Pinargozu Zinc Mine & Akkaya Zinc Project v Red area indicates prospect for zinc district in southern Turkey where Pasinex operates Tufanbeyli Zinc District Yahyali Zinc District v Infrastructure is strong in Turkey. The key to Pasinex being able to ramp up quickly to production was because of readily available infrastructure Pinargozu Zinc Mine & Akkaya Exploration Project Bolkar Zinc District ADANA Route to Port v Access to major roads, port (Mersin), major airport (Adana), HV electrical MERSIN PORT

14 Zinc in the Taurus Mountains JV Area of Interest Main city of Adana 2.2 million Port of Mersin 2½ hours away HV power available Water available Horzum Pinargozu & Akkaya

15 Akkaya Zinc Project [Exploration] v Commence diamond drill-testing at the Akkaya Zinc Property in September 2018 v Compelling drill targets have been generated over the last few months along the proximal HZT through a combination of detailed geological mapping, soil geochemistry (IL) and outcrop lithogeochemistry v Between 500 metres and one kilometre north of the Company s Pinargozu zinc mine.

16 Surface Lithology Map of Pinargozu & Akkaya v Purple indicates White Marble host-rock v Favourable structural settings coincident with the White Marble host-rock v This process of identifying the White Marble host-rock has generated compelling drill targets Quaternary Shale Siltstone Nodular Limestone Mottled Limestone Grey Limestone Marble Dolomitic Limestone Dolomite Quartzite Siltstone Pinargozu Chaotic Unit Mafic Rocks

17 Pinargozu Zinc Mine [Production & Exploration] v High Profit margins (65% in first three quarters of 2018) v Dividends being received v Selling Direct-Shipping natural concentrate on spot (no long term contracts) v Producing mine with ultra high grade zinc v 32% zinc in the Oxides v 42% zinc in the Sulphides v Pinargozu is a new discovery made in 2013 v Exploration underway to expand the resource v Growing expertise in recognizing other high-grade zinc properties like Pinargozu v Turkish JV-Partner with strong operational experience

18 Pasinex Financial Results Q Year-Over-Year Comparison (Canadian Dollars) Q Q Pasinex Resources Limited Equity Gain $521,675 $2,698,696 Net Income (loss) $(194,998) $1,838,461 Dividend Received from Horzum AS - - Zinc Price US $1.15 US $1.34

19 Horzum AS Financial Results Q Year-Over-Year Comparison (Canadian Dollars) Q Q Horzum AS Reporting as 100% Revenues $4,852,494 $9,327,185 Gross Margin 54% 70% Net Income (before taxes) $1,333,214 $6,746,740 Net Income (after taxes) $1,043,350 $5,397,392 Turkish Lira / CAD* Turkish Lira / USD** 4.33 CAD/TRY 5.66 USD/TRY 2.80 CAD/TRY 3.51 USD/TRY * November 30, 2018 CAD/TRY closed at 3.94 ** November 30, 2018 USD/TRY closed at 5.23

20 Horzum AS Financial Results Year to September 2018 and 2017 Year-Over-Year Comparison (Canadian Dollars) Horzum AS Reporting as 100% Revenues $20,955,157 $19,394,413 Gross Margin 65% 60% Net Income (before taxes) $13,636,162 $11,995,850 Net Income (after taxes) $10,623,093 $9,596,680 Turkish Lira / CAD* Turkish Lira / USD** 3.58 CAD/TRY 4.62 USD/TRY 2.74 CAD/TRY 3.59 USD/TRY * November 30, 2018 CAD/TRY closed at 3.94 ** November 30, 2018 USD/TRY closed at 5.23

21 Pinargozu Development v Four adits from hillside now operating v 2018 production of 45,717 tonnes of DSO concentrate v 2019 production guidance of 14,000 17,000 tonnes of DSO concentrate predominately sulphide ore v A mine development program commenced in October 2018 and will take approximately 9 months until June 2019 to reach the deeper sulphide zone v Over 6.0 kilometres of underground development v 300 miners & engineers are working at Pinargozu v Mine safety standards priority focus

22 Pinargozu Production from Multiple Faces v New Adit Project at 550 Level v Plan view of mineralization predominantly zinc carbonates (oxides) and zinc sulphides shown in red area; underground workings shown in other colours 811 Level v Cut and fill mining method v Current production rate 170 tonnes per day of direct shipping product v Production is 85% oxide / 15% sulphide production of DSO grade material 663 Level 550 New Adit Project

23 Pinargozu Production Profile 60,000 57,625 50,000 45,757 40,000 30,000 31,148 20,000 10,000 6,731 10,224 14,000 17, Projection

24 Exploration Conceptual Model v Carbonate replacement type Zn - geological model v Current Pinargozu operation is high up in the manto could be a deep system; lots of exploration opportunity v Skarn opportunity Early in and high up in the manto system

25 Regional Exploration in Turkey v The Pinargozu carbonate replacement zinc project is similar to CRD deposits in Mexico such as Naica v Pinargozu, Akkaya and region v Near mine areas exploring the strike extension of hydrothermally altered marbles. Second Order HZT Splay MAIN HORZUM TREND Second Order HZT Splay Undrilled Main HZT Marble Alteration v There is potential in the district to find more properties like Pinargozu Cambrian Carbonates Zn-Pb Occurances along to HZT Pinargozu Ore Surface Projection Pinargozu Mine HZT: Horzum Trend

26 Zinc 101 v Uses of zinc: v Galvanizing of Steel (making it rust proof) v Car bodies, street lamp posts, safety barriers, suspension bridges v Health: v Sunscreen and vitamins v Zinc Oxides v Paints, rubber, cosmetics, pharmaceuticals, plastics, inks, soaps, textile v Die-casting v Electrical equipment v China is a major consumer v Strong zinc price over the last year v Stocks of Zn continue to drop v What s going to happen to zinc in the next 5 years? v Battery opportunity

27 Contact Details Canada Main Office Pasinex Resources Limited 82 Richmond St. E. Toronto, ON M5C 1P1 Tel +1 (416) Adana Office, Turkey Zeytinli Mah. Turhan Cemal Beriker Blv. No 607 / A Seyhan, Adana Corporate Communications Tel +1 (416) evan.white@pasinex.com General Information info@pasinex.com

28 PASSION IN EXPLORATION The way to build a zinc company is one mine at a time - Steve Williams

January A different kind of Zinc Explorer

January A different kind of Zinc Explorer January 2018 A different kind of Zinc Explorer Cautionary Statement This presentation contains certain statements that may be deemed "forward-looking statements". All statements in this presentation, other

More information

Mutiny continues to hit high grade gold and copper intersections in latest Deflector drilling

Mutiny continues to hit high grade gold and copper intersections in latest Deflector drilling Mutiny continues to hit high grade gold and copper intersections in latest Deflector drilling New Diamond drill results within the Deflector Deposit include: 3.3m @ 79g/t Au and 10.5% Cu from 62m in 12DD042

More information

Disclaimer. Matrix Metals Limited Presentation October

Disclaimer. Matrix Metals Limited Presentation October Matrix Metals Limited Presentation October 2008 Disclaimer The material used is this presentation is intended to be a summary of selected geological data, current and proposed activities, as well as resource

More information

Riesling Base Metal Project pxrf Soil Geochemistry

Riesling Base Metal Project pxrf Soil Geochemistry pxrf Soil Geochemistry Ken Harvey Non-executive Director Superior Resources Limited Riesling Located 280km NW Townsville & 17km SSW of Mount Surprise, North Queensland VMS (or Broken Hill) type deposit

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

First Results Prospector Drilling Program

First Results Prospector Drilling Program 24 June 2008 Manager Company Announcements Company Announcements Office Australian Stock Exchange Limited Level 10, 20 Bond Street SYDNEY NSW 2000 ABN 42 082 593 235 Electronic delivery No of pages: 10

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

TRI ORIGIN MINERALS LTD

TRI ORIGIN MINERALS LTD TRI ORIGIN MINERALS LTD Mines And Wines Conference September 2007 Woodlawn Zinc-Copper Projects ASX Code: TRO DISCLAIMER The Information contained in this presentation has been prepared using the information

More information

Investment in MGC Pharmaceuticals

Investment in MGC Pharmaceuticals Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information

More information

Korean Airlines Q Results

Korean Airlines Q Results Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and

More information

Ayawilca Zinc Project Peru: Targeting Resource Growth in 2017

Ayawilca Zinc Project Peru: Targeting Resource Growth in 2017 Ayawilca Zinc Project Peru: Targeting Resource Growth in 2017 PDAC Peru Day Presentation Dr Graham Carman Tinka Resources Limited March 6, 2017 OTC: TKRFF Disclaimer This presentation is not directed to,

More information

Developing Xanamem for Alzheimer s Dementia

Developing Xanamem for Alzheimer s Dementia Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen

More information

For personal use only

For personal use only Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by

More information

World leader in navigated, non-invasive brain stimulation therapy and diagnosis

World leader in navigated, non-invasive brain stimulation therapy and diagnosis World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

Macmillan Pass Zinc Project: Growing an Already World-Class Asset

Macmillan Pass Zinc Project: Growing an Already World-Class Asset Macmillan Pass Zinc Project: Growing an Already World-Class Asset January 2018 Cautionary Statements The following statements are required by Canadian securities legislation: Forward-Looking Statements:

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

GI Dynamics, Inc. Q2 16 Quarterly Shareholder Brief 8/11/16

GI Dynamics, Inc. Q2 16 Quarterly Shareholder Brief 8/11/16 GI Dynamics, Inc. Q2 16 Quarterly Shareholder Brief 8/11/16 Forward Looking Statements Currency References Financial amounts in this presentation are expressed in US Dollars, except where specifically

More information

BISIE PROJECT UPDATE

BISIE PROJECT UPDATE Level 3, Gotthardstrasse 20, CH-6300, Zug, Switzerland Tel: +41 41 711 02 81 www.alphaminresources.com BISIE PROJECT UPDATE News Release 2014-10-27 VANCOUVER, CANADA October 27 th, 2014 Alphamin Resources

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

DNI Metals - First 12 of 28 Diamond Core Assays Received; Including 34m Grading 5.63% Graphitic Carbon

DNI Metals - First 12 of 28 Diamond Core Assays Received; Including 34m Grading 5.63% Graphitic Carbon DNI Metals - First 12 of 28 Diamond Core Assays Received; Including 34m Grading 5.63% Graphitic Carbon Toronto, Ontario--(Newsfile Corp. - December 7, 2017) - DNI Metals Inc. (DNI: CSE) (FSE: DG7N) (OTC

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

For personal use only

For personal use only Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation April 2015 Forward Statements 2For personal use only This presentation has been prepared by Actinogen

More information

28 April 2017 ASX Code: COY. March 2017 Quarterly Activity Report

28 April 2017 ASX Code: COY. March 2017 Quarterly Activity Report 28 April 2017 ASX Code: COY The following report details the operating and corporate activities of Coppermoly Ltd (Coppermoly or the Company) for the quarter ended 31 March 2017 and to the date of this

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

NET LEASE INVESTMENT OFFERING RITE AID PHARMACY

NET LEASE INVESTMENT OFFERING RITE AID PHARMACY RITE AID PHARMACY 11702 Lorain Avenue Cleveland, OH 44111 TABLE OF CONTENTS TABLE OF CONTENTS I. Executive Profile Executive Summary Investment Highlights Property Overview II. Location Overview Photographs

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,

More information

Molecular Diagnostic Solutions for Urologic Cancer

Molecular Diagnostic Solutions for Urologic Cancer 1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This

More information

Company overview. Highlights for the 1 st quarter 2018 (January-March)

Company overview. Highlights for the 1 st quarter 2018 (January-March) Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

Advancing Pancreatic & Liver Cancer Treatment

Advancing Pancreatic & Liver Cancer Treatment ASX.OSL Advancing Pancreatic & Liver Cancer Treatment Australian Biotech Invest 2017 October 24 th Melbourne 1 Important notice This Presentation has been prepared by Ltd (ASX:OSL) (OncoSil or the Company)

More information

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final

More information

PROACTIVE INVESTOR PRESENTATION

PROACTIVE INVESTOR PRESENTATION www.thcl.com.au ASX RELEASE (16 th May 2017) PROACTIVE INVESTOR PRESENTATION The Hydroponics Company Limited (ASX: THC) is pleased to advise that Dr Andrew Beehag, Chief Executive Officer of Canndeo Limited,

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Investor presentation. Bioshares Biotech Summit July 2017

Investor presentation. Bioshares Biotech Summit July 2017 Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness

More information

Summary Statement of Financial Position (consolidated)

Summary Statement of Financial Position (consolidated) 2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,

More information

Mental Toronto Hydro

Mental Toronto Hydro Mental Health @ Shirley Powell, Director, HR Planning, Systems & Rewards Benefits Canada s 2015 Healthy Outcomes Conference June 9-11, 2015 Niagara-on-the-Lake Company Overview Established in 1911 Largest

More information

Important Notices. BASIS CPD Points PN/50971/1516/g

Important Notices. BASIS CPD Points PN/50971/1516/g Chilli pepper results May 2016 1 Important Notices BASIS CPD Points PN/50971/1516/g This document is produced for information only and not in connection with any specific or proposed offer (the Offer )

More information

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites

More information

Passion for progress, care for people

Passion for progress, care for people Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation June 2012 NASDAQ: CEMI Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act

More information

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes Sébastien Bolze 1 ; Sophie Hallakou-Bozec 1 ; Michael Roden 2, 3,4 ; Julien Roux

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

PATENCY-1 Top-Line Results

PATENCY-1 Top-Line Results PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease

XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease Dr Bill Ketelbey CEO 17TH ALZHEIMER'S AUSTRALIA BIENNIAL NATIONAL DEMENTIA CONFERENCE 19 OCTOBER 2017 Disclaimer This presentation has

More information

Leading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF

Leading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Leading Cannabinoid Patient Care in Canada Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Forward Looking Statements Except for historical information, this presentation contains forward-looking

More information

TSX: LUN OMX: LUMI Corpora Corpor t a e t Presen esen a t tion

TSX: LUN OMX: LUMI Corpora Corpor t a e t Presen esen a t tion TSX: LUN OMX: LUMI Corporate Presentation November 2013 Cautionary Statements Caution Regarding Forward Looking Statements This presentation contains forward looking statements. These forward looking statements

More information

THE VILLAGE AT SAVANNAH QUARTERS

THE VILLAGE AT SAVANNAH QUARTERS THE VILLAGE AT SAVANNAH QUARTERS POOLER PARKWAY POOLER, GA 31322 Adam Bryant, CCIM Partner 912.667.2740 adam.bryant@svn.com Tom DeMint, CCIM Partner 843.816.7191 tdemint@svn.com SVN GASC 6001 CHATHAM CENTER

More information

Third-quarter results 2013

Third-quarter results 2013 Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

Making a difference through health How PwC is helping to change lives

Making a difference through health How PwC is helping to change lives Making a difference through health How PwC is helping to change lives Impact case studies www.pwc.com/global-health Introduction Making a difference through health PwC s purpose is to build trust in society

More information

NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX

NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,

More information

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call

More information

ASX/Media Announcement 24 December 2010

ASX/Media Announcement 24 December 2010 ASX/Media Announcement 24 December 2010 ANDY WELL PROJECT UPDATE Diamond drilling continues to deliver high-grade results RC drilling continues at Wilber Lode to define a JORC Resource Southern extensions

More information

RISK ALLOCATION IN TRANSPORTATION INFRASTRUCTURE PROJECTS

RISK ALLOCATION IN TRANSPORTATION INFRASTRUCTURE PROJECTS RISK ALLOCATION IN TRANSPORTATION INFRASTRUCTURE PROJECTS Hans Dekker President, Infrastructure 2016 Fluor Corporation ECRI Amsterdam 02016 Agenda Fluor Profile Infrastructure Business Line Tappan Zee

More information

Global Zinc Chemicals Market Study ( )

Global Zinc Chemicals Market Study ( ) Global Zinc Chemicals Market Study (2014 2025) Table of Contents 1. INTRODUCTION 1.1. Introduction to Zinc Chemicals Market Product Description Properties Industry Structure Value Chain Market Dynamics

More information

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation

More information

2018: Growing & De-risking the Ayawilca Zinc Project in Peru

2018: Growing & De-risking the Ayawilca Zinc Project in Peru TSXV & BVL:TK OTCPK: TKRFF www.tinkaresources.com 2018: Growing & De-risking the Ayawilca Zinc Project in Peru Corporate Presentation May 2018 Disclaimer This presentation is not directed to, or intended

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

Brisa Concessão Rodoviária. 1Q 2017 Traffic Update

Brisa Concessão Rodoviária. 1Q 2017 Traffic Update Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according

More information

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

Pierre Legault CEO June 2, 2014

Pierre Legault CEO June 2, 2014 April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment

Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment Rachael Eckles, JD/MA Director, Regulatory Policy Bristol-Myers Squibb August 10,

More information

The Dental Corporation Opportunity

The Dental Corporation Opportunity The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,

More information

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance- Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer MagSense Technology A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer Company Overview October 2017 ASX:IBX www.imagionbiosystems.com Disclaimer This presentation has been prepared

More information

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission

More information

RULES OF CONDUCT OF INSIDERS RESPECTING

RULES OF CONDUCT OF INSIDERS RESPECTING T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )

More information

For personal use only

For personal use only ASX: VRX Diggers & Dealers August 2012 Bruce Maluish, Managing Director www.ventnorresources.com.au 1 Disclaimer & Competent Person This presentation was prepared with due care and attention and is current

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company

More information

Halton Region. Business Conditions

Halton Region. Business Conditions Halton Region Business Conditions 2014 Message from Regional Chair Gary Carr Time and again, innovative business owners in Halton tell me that Halton is a great place to live and work because we offer

More information

PVD (PVDrilling) Company Visit October 2011

PVD (PVDrilling) Company Visit October 2011 PVD (PVDrilling) Company Visit October 2011 2011 Preview: 3Q11 EBT margin is expected to be higher than 2Q11 largely due to no booking of provision for Science and Technology Development Fund According

More information

Corporate Presentation. October 2017

Corporate Presentation. October 2017 AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

Zealand Pharma A/S Interim report for Q (un-audited)

Zealand Pharma A/S Interim report for Q (un-audited) Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical

More information

Vestavia Hills, City of, AL

Vestavia Hills, City of, AL Vestavia Hills, City of, AL 1 City of Vestavia Hills, Alabama, General Obligation Warrants, Series 2016, $11,810,000, Dated: July 14, 2016 2 City of Vestavia Hills, Alabama, General Obligation Warrants,

More information

GF China Commodities Weekly

GF China Commodities Weekly GF China Commodities Weekly CHINA ZINC CONCENTRATE SUPPLY WILL BE MORE DEPENDENT ON DOMESTIC MARKETIN 2H16 GFF Commodities Research Contacts : Bonnie Liu;852-3719 1155;bonnieliu@gfgroup.com.hk Zhang Ruoyi;020-85594189;zhangruoyi@gf.com.cn

More information

which has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy.

which has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy. News Release April 10, 2018, Kelowna, BC Marapharm Ventures Inc. To Introduce Organic CBD Health and Wellness Products To Be Featured In Its California Dispensary Marapharm Ventures Inc. (CSE: MDM) (OTCQX:

More information

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data

More information

HISTORICAL OVERVIEW OF GOLD COPPER MINERAL DISCOVERIES & MINE DEVELOPMENTS IN THE PHILIPPINES

HISTORICAL OVERVIEW OF GOLD COPPER MINERAL DISCOVERIES & MINE DEVELOPMENTS IN THE PHILIPPINES 15 10 05 120 125 120 125 15 10 05 HISTORICAL OVERVIEW OF GOLD COPPER MINERAL DISCOVERIES & MINE DEVELOPMENTS IN THE PHILIPPINES Spain China 3rd 1 th century North America Java 16 th 19 th century12 th

More information

Investor Presentation

Investor Presentation Investor Presentation January 2012 Forward Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,

More information

SWEDISH MATCH RESULTS PRESENTATION Q3 2017

SWEDISH MATCH RESULTS PRESENTATION Q3 2017 SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information